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Abstract
Purpose Adipokines produced by white adipose tissue are central in the development of lifestyle diseases. Individuals in
industrialized countries spend a substantial part of life in the non-fasting, postprandial state, which is associated with increased
oxidation and inflammation. The aim was to study postprandial adiponectin and leptin levels after an oral fat tolerance test
(OFTT) and an oral glucose tolerance test (OGTT) in obese (OB) and healthy, normal weight individuals (NW).
Methods Fifty adults with obesity (BMI ≥ 30) and 17 healthy, NW were included. Postprandial triglyceride (TG), adipo-
nectin, and leptin levels were measured every second hour during an 8 h OFTT, and every half hour during a 2 h OGTT.
Results Compared with the basal level, postprandial levels of adiponectin following OFTT showed a slight initial peak,
followed by a significant decrease at 8 h, in the NW. In the OB these changes were abolished. Postprandial levels of leptin
decreased significantly from basal levels in the OFTT, in the NW, whereas in the OB, leptin was unchanged except for a
slight increase from 2 to 8 h. During the OGTT both adiponectin and leptin levels remained unchanged in the NW, but
decreased significantly in the OB. In addition, the OB had delayed TG clearance at 6 h.
Conclusions A fatty meal gives postprandial changes in the secretion of adiponectin and leptin in NW, but not in OB. Our
observations indicate that a potential postprandial regulatory role of adiponectin and leptin is impaired in OB, and of
importance in a more comprehensive understanding of the delayed postprandial TG clearance in obese individuals.
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Overweight and obesity are raising global health problems
with several metabolic disturbances and comorbidities, such
as type 2 diabetes and cardiovascular disease (CVD). CVD
by itself is the leading cause of morbidity and mortality in
industrialized countries, with obesity as an independent risk
factor [1], and it was the main cause of death worldwide in
2012 [2].
In obesity the amount of white adipose tissue (WAT) is
increased. WAT is a highly metabolically active endocrine
organ (for review, see Ahima [3]). More than 600 adipo-
kines have been described thus far [4], among which are
leptin and adiponectin [3]. Increased levels of leptin,
which is the case in obesity and leptin resistance (LR), are
directly or indirectly associated to CVD [5]. In contrast,
adiponectin, which is reduced in the obese and diabetic
state, has shown to have protective and anti-atherogenic
actions, opposing hyperglycemia, inflammation, lipotoxic
damage, and insulin resistance (IR) [6, 7]. Furthermore,
both leptin and adiponectin may facilitate responses of
fibroblast growth factor 21 (FGF-21), which has effect on
energy expenditure and whole-body glucose metabolism.
FGF-21 is also a potent regulator of adiponectin secretion
[8]. However, there are diverging reports about the role of
adiponectin. In individuals with chronic illness and low
body mass index (BMI), recent studies show that adipo-
nectin might be associated with increased all-cause mor-
tality, as well as increased cardiovascular mortality; the
adiponectin-paradox [9–11]. Furthermore, adipokines play
a pivotal role in the inflammation process and in the
development of non-alcoholic-fatty liver disease (NAFLD)
(for review, see Boutari [12]).
Individuals in industrialized countries spend a sub-
stantial part of life in the non-fasting, postprandial state,
which is associated with increased oxidation and inflam-
mation. Postprandial hyperlipidemia has been associated
with overweight [13] and abdominal obesity [14–17] and
is an independent risk factor for atherosclerosis. Fur-
thermore, our knowledge of postprandial changes of
leptin and adiponectin in normal weight and obese indi-
viduals is limited. The results are diverging, both for
postprandial leptin and adiponectin secretion, with reports
of no postprandial changes in leptin [18–20], as well as
increased postprandial leptin levels in normal weight
controls and decreased in obese individuals [21, 22]. For
adiponectin, reports have found both increased [23–25]
and unchanged [25–29] for both normal weight and obese
individuals.
Due to the diverging results of the postprandial profile of
adiponectin and leptin secretions both in normal weight and
obese individuals, the aim of this study was to explore
leptin and adiponectin in the postprandial state, in response
to a fat and a carbohydrate load, separately, in obese and
healthy, normal weight individuals.
Methods
Participants
Volunteers were recruited from the Centre of Obesity,
Department of Gastroenterology, at the University Hospital
of North Norway (UNN). The inclusion criteria for the obese
individuals were BMI ≥ 30 kg/m2 and age 18–70 years.
Exclusion criteria were pregnancy, current smoking, serious
mental illness, and the use of medications to induce weight
loss. The inclusion and exclusion criteria for the normal
weight (BMI < 25 kg/m2) were the same, in addition to being
normotensive, normoglycemic and to have triglycerides and
cholesterol levels within the normal range. All of the study
individuals had thyroxin (T4) and thyroid-stimulation hor-
mone (TSH) levels within the normal range. All of the par-
ticipants in the study were Caucasian.
Height, body weight, and waist circumference were
measured. Blood pressure was measured three times on the
right arm, after a 15-min rest. Appropriate cuff size was used.
The mean of the two last measurements was used. All blood
samples were collected at the laboratory, and at the same day,
for the analysis of fasting glucose, total cholesterol, low-
density lipoprotein (LDL) cholesterol, high-density lipopro-
tein (HDL) cholesterol, and fasting TG. The samples were
taken from the antecubital vein, with the patient in a seated
position. Serum lipids and apolipoprotein were measured
according to a previous report from our group [30].
Dual X-ray absorptiometry (DEXA, Lunar Prodigy
Advance, GE healthcare, USA) measurements were col-
lected of all the study participants. The DEXA measured
total fat percent, abdominal fat percent, total fat mass (kg),
and total muscle mass (kg).
Oral fat tolerance test
The oral fat tolerance test (OFTT) has proven to be a good,
indirect and qualitative measure of postprandial TG clear-
ance [31]. OFTT was performed as previously described,
whereas most of the data from normal weight individuals
have been published previously [30]. In short, blood sam-
ples for serum TG were collected at baseline before the
high-fat test meal (1 g fat per kg body weight) and thereafter
every second hour over the next 8 h. The TG clearance at
6 h was calculated by the following formula:
Clearance 6hð Þ ¼ 100  1 TG 6hð ÞTG 0hð ÞTG maxð Þ TG 0hð Þ
 
. We have
previously demonstrated that the postprandial TG clearance
at 6 h was the most suitable measure [30].
518 Endocrine (2019) 66:517–525
Oral glucose tolerance test
A standard oral glucose tolerance test (OGTT) was con-
ducted after 12 h fasting, using an oral intake of 75 g glu-
cose as previously described [30]. Glucose and insulin were
measured every half hour for 2 h, and the individuals were
at rest during the whole test. Serum insulin was analyzed
directly by ELISA (DRG Insulin Elisa kit, DRG Instru-
ments GmbH, Germany). IR determination was done by the
homeostasis model assessment for IR (HOMA-IR) [32–34],
and was calculated as followed: HOMA-IR= Fasting
insulin (μmol /L) × Fasting glucose (mmol/L)/22.5 [35].
Indirect leptin resistance
We wanted to measure indirect LR, for comparison between
the normal weight and the obese individuals. Resting energy
expenditure (REE) measurements were performed by a
canopy test with an indirect calorimetry device from Medical
Graphics CPX metabolic cart (St Paul, MN, USA). The
indirect calorimetry was performed in a supine position.
Before start, the O2 and CO2 analyzers were calibrated (a
combined internal and manual adjustment system), based on
the ambient temperature and barometric pressure. In addition,
the breathing capacity analyzer was calibrated with a three-
calibration syringe using multiple measures. Measurements
were taken in a resting and fasting state for 30min. REE was
derived from the respiratory exchange ratio and the respiratory
quotient. At the completion of the REE, blood samples for
measurements of serum leptin and adiponectin were obtained.
Indirect LR was measured as; REE to serum leptin ratio [36].
Measurements for adipokines
ELISA kits (DRG Diagnostics, Marburg, Germany) were
used to analyze the adipokines leptin (sandwich ref. EIA-
2395) and adiponectin (human, ref. EIA-4574) at baseline
and postprandial during OFTT and OGTT.
Statistics
Statistics were calculated on IBM SPSS 25 for Windows
(SPSS Inc., IBM Corporation, Armonk, New York, USA).
Parametric statistics were performed when the raw data
(fasting glucose, fasting leptin and L:A ratio) or transformed
data (Indirect LR, HOMA-IR and WBISI), using log trans-
formation, followed a normal distribution using; otherwise,
non-parametric tests were used. Tests for independent or
paired samples were used as appropriate. Two-sided
p-values < 0.05 were considered statistically significant.
Repeated measures analysis of variance (RM-ANOVA) was
used to analyze the postprandial timeline for normal weight
individuals and obese individuals. We also did a subgroup
analysis of only females, 15 normal weight and 40 obese
females. Corrections of violations of sphericity were used as
appropriate, according to the epsilon value.
Results
Anthropometric, metabolic- and clinical
characteristics
Fifty obese and 17 normal weight individuals was included
in the study, of these 40 obese and 15 normal weight
females. Of the obese individuals; five had elevated fasting
TG (≥1.7 mmol/L), three patients had untreated hyperten-
sion (≥130/ ≥ 85 mmHg), six patients had reduced HDL
cholesterol (Women < 1.29 mmol/l, men < 1.03 mmol/L),
and six patients had elevated fasting glucose (≥5.6 mmol/L).
Furthermore, ten individuals had hypertension regulated
within the normal range with antihypertensive medication
(Ibersartan, Hydrochlortiazide, Losartan, Amlodipin, Ena-
lapril, Selo-Zok), five individuals had type 2 diabetes
(regulated with lifestyle, no anti-diabetes medication), eight
patients used lipid lowering drugs (Simvastatin, Atorvasta-
tin), and four patients were treated for hypothyreosis. The
obese patients that were treated for hypothyreosis had
started their medication years ago, were well substituted
with stable T4 and TSH, within the normal range, and their
bodyweight was stable before the study. Anthropometric,
metabolic- and clinical characteristics of obese individuals
and normal weight individuals are shown in Table 1. As
expected, there were several significant differences; espe-
cially a higher baseline adiponectin and lower baseline
leptin in the normal weight individuals compared with the
obese individuals. Furthermore, delayed postprandial TG
clearance at 6 h, lower insulin sensitivity, and higher
indirect LR, were found in obese individuals compared with
normal weight individuals (Table 1). Fasting leptin (OFTT)
had a significant, positive correlation to fasting insulin (rs=
0.446, p= 0.000) and fasting glucose (rs= 0.264, p=
0.048), but not to fasting TG (rs= 0.204, p= 0.112) or TG
clearance 6 h (rs=−0.257, p= 0.053). Fasting adiponectin
(OFTT) had a significant, negative correlation to fasting TG
(rs=−0.333, p= 0.008), fasting insulin (rs=−0.542, p=
0.000), and significant positive correlation to TG clearance
6 h (rs= 0.314, p= 0.012), but not to fasting glucose (rs=
−0.203, p= 0.127).
Oral fat tolerance test
Postprandial triglycerides after oral fat tolerance test
Normal weight individuals When comparing fasting TG
with postprandial TG levels, in normal weight individuals,
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there was a significant increase in TG at 2 h (p= 0.000), and
close to significant increase at 4 h (p= 0.062) and 8 h (p=
0.084) during the OFTT (Fig. 1c and Supplementary Table 2).
Obese individuals When comparing fasting TG with
postprandial TG levels, in obese individuals, there was a
significant increase in TG at 2 h (p= 0.000), 4 h (p= 0.000)
and 6 h (p= 0.000) (Fig. 1c and Supplementary Table 2).
Postprandial adiponectin after oral fat tolerance test
Normal weight individuals For the healthy, normal weight
individuals, when compared with baseline values there was a
slight, non-significant, increase of adiponectin at 2 h (p=
0.052), and a subsequent significant decrease towards 8 h
postprandial (p= 0.046) (Fig. 1a and Supplementary Table 2).
Normal weight individuals (females only) For the healthy,
normal weight individuals, when compared with baseline
values there was a significant increase of adiponectin at 2 h
(p= 0.026), and a subsequent non-significant decrease
towards 8 h postprandial (p= 0.068).
Obese individuals In the obese individuals, when com-
pared with baseline values there were no significant dif-
ferences in adiponectin levels postprandial during the OFTT
(Fig. 1a and Supplementary Table 2).
Obese individuals (females only) For the obese individuals,
when compared with baseline values there were no significant
differences in adiponectin levels postprandial during the OFTT.
Postprandial leptin after oral fat tolerance test
Normal weight individuals When compared with baseline
values the postprandial leptin levels were significantly
decreased at 2 h (p= 0.001), 4 h (p= 0.001), 6 h (p=
0.001) and 8 h (p= 0.004). Compared with adiponectin an





weight subjects and obese
subjects. Values are median
(Interquartile range)
Baseline





Sex (M/F) 2/15 10/40 n.s.
Age (years) 31.0 (24.5; 37.5) 39.8 (30.8; 48.8) <0.01
BMI (kg/m2) 21.3 (20.2; 22.4) 39.8 (36.0; 43.6) <0.001
Total fat percent (%) 26.6 (23.7; 29.6) 50.4 (46.4; 54.5) <0.001
Abdominal fat percent (%) 27.5 (24.3; 30.7) 57.6 (54.7; 60.6) <0.001
Systolic BP (mmHg) 105 (98; 113) 127 (118; 136) <0.001
Diastolic BP (mmHg) 65 (60; 70) 75 (68; 81) <0.001
Fasting Glucose (mmol/L) 4.4 (4.0; 4.7) 5.3 (4.8; 5.7) 0.001M
Fasting Insulin (μmol/L) 5.53 (4.08; 6.99) 12.12 (8.14; 16.10) 0.001
HOMA-IR 1.09 (0.37; 1.11) 2.76 (1.82; 4.17) <0.001G
WBISI 147.8 (97.1; 198.6) 59.6 (42.7; 83.2) <0.001G
Fasting leptin (μmol/L) 8.5 (4.8; 12.2) 39.2 (24.3; 54.1) <0.001M
Fasting adiponectin (μmol/L) 11.8 (8.2; 15.3) 8.1 (5.9; 10.3) 0.001
Leptin/Adiponectin ratio 0.77 (0.31; 1.23) 4.26 (1.55; 6.97) <0.001M
Resting energy expenditure,
REE (kcal)
1356 (1263; 1448) 1734 (1526; 1943) <0.001
Indirect leptin resistance (REE/
leptin OFTT)
142.5 (75.5; 209.5) 47.5 (31.0; 72.7) <0.001G
Total cholesterol (mmol/L) 4.2 (3.8; 4.7) 4.4 (3.9; 4.9) n.s.
LDL cholesterol (mmol/L) 2.6 (2.0; 3.3) 2.9 (2.4; 3.4) n.s
HDL cholesterol (mmol/L) 1.6 (1.4; 1.9) 1.1 (1.0; 1.3) <0.001
HDL/ LDL ratio 0.57 (0.33; 0.82) 0.41 (0.29; 0.54) <0.01
Fasting triglycerides (mmol/L) 1.0 (0.8; 1.2) 1.4 (1.1; 1.8) <0.001
Triglyceride clearance 6 h (%) 115.4 (39; 226.5) 58.0 (0; 193) <0.001
GGeometric mean
MMann–Whithey non-parametric test
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Normal weight individuals (females only) When com-
pared with baseline values the postprandial leptin levels
were significantly decreased at 2 h (p= 0.001), 4 h (p=
0.001), 6 h (p= 0.001) and 8 h (p= 0.003). Compared
with adiponectin an initial increase of leptin was not
observed.
Obese individuals When compared with baseline values
the postprandial leptin levels were unchanged at all time
points (Fig. 1b and Supplementary Table 2), but they had a
slight, non-significant, increase at 8 h (p= 0.052).
Obese individuals (females only) When compared with
baseline values the postprandial leptin levels were
unchanged at all time points, but they had a slight, non-
significant, increase at 8 h (p= 0.054).
Oral glucose tolerance test
Postprandial adiponectin after oral glucose tolerance test
Normal weight individuals When compared with base-
line levels there was a non-significant trend towards
increased adiponectin at 30 min (p= 0.064) (Fig. 2a and
Supplementary Table 3).
Normal weight individuals (females only) When compared
with baseline levels there were no significant changes in
adiponectin during OGTT in females.
Obese individuals Compared with baseline values of adi-
ponectin there was a significant decrease of adiponectin at
90 min (p= 0.009) (Fig. 2a and Supplementary Table 3).
Obese individuals (females only) When compared with
baseline levels, adiponectin had a gradual and significant
decrease at 90 min (p= 0.013), and also at 120 min (p=
0.009) during OGTT in females.
Postprandial leptin in oral glucose tolerance test
Normal weight individuals When compared with the
baseline values leptin decreased slightly (Fig. 2b and Sup-
plementary Table 3), but not significant (n.s.).
Normal weight individuals (females only) When compared
with baseline levels there were no significant changes in
adiponectin during OGTT in females.
Obese individuals When compared with baseline levels,
leptin had a gradual and significant decrease at all time
Fig. 1 Oral fat tolerance test. Eight hours oral fat tolerance test in normal weight (circle) and obese (square) individuals measuring adiponectin
(panel a), leptin (panel b), and triglycerides (panel c). Significant differences (p < 0.05) from baseline values are marked * in the separate groups
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points 30 min, 60 min, 90 min, and 120 min (all: p= 0.000)
during OGTT (Fig. 2b and Supplementary Table 3).
Obese individuals (females only) When compared with
baseline levels, leptin had a gradual and significant decrease
at all timepoints 30 min (p= 0.000), 60 min (p= 0.011),
90 min (p= 0.000), and 120 min (p= 0.001) during OGTT
in obese females.
As expected, both insulin and glucose increased sig-
nificantly at all time points in both groups during the OGTT
(Fig. 2c, d). The obese individuals had significant higher
basal (Table 1) and postprandial levels of both insulin and
glucose, as expected. No measurements of glucose and
insulin were done in the OFTT.
Discussion
In this study we report postprandial adiponectin, leptin, and
TG responses after an 8 h fat load and a 2 h carbohydrate
load in normal weight and obese individuals. In addition to
insulin resistance, indirect leptin resistance was observed in
the obese individuals, in addition to delayed TG clearance.
In general, an apparent time effect of a postprandial sup-
pression of leptin and adiponectin was observed in normal
weight individuals in response to a fat load, whereas these
regulations were more or less abolished in the obese indi-
viduals. These results were also supported by doing analysis
only in normal weight and obese females. Our data indicate
that adiponectin and leptin might have a postprandial reg-
ulatory role that can be overruled in obese individuals.
These interactions are tightly associated to postprandial TG
clearance in an apparent complex and not well understood
regulatory mechanisms in the white adipose tissue.
The postprandial adiponectin levels observed in response
to a fat load in our study is in conflict with other studies. In
normal weight individuals, other studies have found post-
prandial adiponectin to be both increased [23, 24], or
unchanged [25–28], whereas in obese individuals both
increased [25] and unchanged levels [26, 29] have been
observed. The early, slight increase of adiponectin seen in
our study, after a fat load, indicates that there might be a
triggered exocytic pathway in the adipocyte. This is sup-
ported from studies in mice, where a response time of
10–45 min for translocation of adiponectin to the plasma
membranesome [8]. In mice exogenous adiponectin
enhanced free fatty acid (FFA) oxidation by activating the
adenosine monophosphate-activated protein kinase, to
reduce the postprandial FFA increase [37, 38]. Based on
these reports, and our observations, the exact physiological
role of adiponectin is still hard to understand. Most likely,
adiponectin appears to play a tuning role in FFA oxidation
especially in fat tissue to accommodate storage of post-
prandial excess of TG, to enhance FFA oxidation in skeletal
muscle, to improve insulin sensitivity and to suppress glu-
cose production in liver (for review, see Wang [39]). This is
mainly achieved by a large number of hormones released
from each organ.
Fig. 2 Oral glucose tolerance
test. Two hours oral glucose
tolerance test in normal weight
(circle) and obese (square)
individuals measuring
adiponectin (panel a), leptin
(panel b), insulin (panel c), and
glucose (panel d). Significant
differences (p < 0.05) from
baseline values are marked * in
the separate groups
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Recently, much attention has been on the FGF-21-
adiponectin axis [8], which has been proposed to protect
against a various cardio-metabolic disorders via mediating
multi-organ communications (for review, see Hui [40]). It
has been proposed that FGF-21 regulates postprandial lipid
metabolism and permits better clearance of triglyceride-rich
lipoprotein fractions [41], especially in healthy individuals,
and that adiponectin might mediate this response. In our
study there was a trend towards a slight, non-significant,
increase of adiponectin 2 h in the OFTT, followed by a
significant decrease, in normal weight individuals, whereas
no changes in the obese individuals. Therefore, it is
tempting to speculate that the fat induced response of adi-
ponectin observed in the normal weight individuals in our
study, could be explained by an FGF-21 mechanism, but
this FGF-21-adiponectin axis is overruled in obesity, per-
haps due to FGF-21 resistance. Furthermore, a report has
also shown that impaired leptin signaling, in relation to
increased caveolin-1-expression, in obesity, may prevent a
concordant increase in adiponectin despite high levels of
leptin [42]. This might indicate that leptin resistance and
adiponectin resistance are connected in complex mechan-
isms. One might also speculate that leptin resistant indivi-
duals, has a different postprandial profile than leptin
sensitive individuals. However, this awaits future studies
that have the correct study design to explore this further.
None of the individuals included in this study had heart
failure, CVD, low BMI, or renal disease. In individuals
with these conditions, adiponectin has shown to be high,
and related to mortality; the adiponectin-paradox [9–11].
This is most likely because of higher levels of brain nat-
uretic peptide, and is also connected to individuals with
cachexia (for review, see Woodward [43]). It is unknown
whether adiponectin resistance also has a role in this pro-
cess. Further studies are needed on this patient group to
explore postprandial adiponectin levels, but also post-
prandial leptin levels.
The postprandial leptin response to a fat load was sig-
nificantly decreased at 2–8 h in normal weight individuals;
on the contrary, the obese individuals had a slightly
increased leptin at 8 h, however non-significant. These
results contradict for the most other reports. For normal
weight individuals, one study showed that leptin decreased
at 6 h [44] such as in our study, unchanged in other studies
[18, 19], whereas an increase was observed in other reports
[20–22]. In obese individuals two reports showed a sig-
nificant postprandial decrease in leptin [21, 22], as well as
no postprandial leptin changes were observed in other stu-
dies [18, 19]. Finally, opposite to our observation of the
secretion of adiponectin, no initial close to significant,
increase of leptin was observed. This is in agreement with a
report that human leptin secretion has a constitutively slow
profile [45]. The discrepancies between these reports are
hard to explain but can to some extent be explained by
differences in the postprandial observation time, that for
most studies were less than 3 h. In addition, the studies
often have a small study group. Altogether, the exact
postprandial physiological role of leptin, if any, is still
unsettled. However, it is tempting to speculate that leptin
increases the postprandial FFA oxidation (expenditure) in
healthy, normal weight individuals, at least in muscle tissue
[46], and that this is abolished in obese individuals with
established leptin resistance. This may explain the delayed
TG clearance; however, this awaits further studies.
There is increasing knowledge of adipocyte physiology
that act to nutritional changes, that by systemic effect either
can be beneficial, or harmful with various metabolic dis-
turbances, such as in obesity. This is most likely a fine tuning
of interactions in the adipokine and myokine secretome.
Moreover, the cell biology of the fat expansion is complex,
but the increased understanding of the pathophysiological
changes in the fat tissue explaining the detrimental systemic
effects (for review, see Rutkowski [47]). Our observations
suggest that a postprandial increase of TG trigger a fine
tuning adipokine response in normal weight individuals, but
is overruled in obese patients with leptin resistance, and most
likely also with adiponectin resistance [48].
The strengths of this study are, first, individuals were
included from the everyday practice at the obesity out-
patient clinic, which underlines the clinical utility and
transferability of our observations. Second, the postprandial
measurements of the adipokines were done over a long
observation time of 8 h for the fat-load and 2 h for the
carbohydrate load, and documented the TG clearance.
Third, the number of study participants was higher than
previous studies that have investigated postprandial adipo-
kines. The most prominent weaknesses are, first, a lack of
match between the groups studied according to number of
individuals, sex and age. Moreover, we did not measure or
record any type of exercise, nor did we monitor the diet, or
intake of different types of fat, as for example N-3-PUFA in
the period before the postprandial studies. Finally, a model
of adipokine measurements directly in interstitial fat tissue
is highly preferable to get a more precise postprandial
response profile of adipokines.
Conclusion
In conclusion, postprandial changes were observed in both
adiponectin and leptin suggesting a physiological role after
a fatty meal in normal weight individuals. In obese indivi-
duals with leptin resistance and delayed TG clearance, these
regulatory mechanisms seem to be overruled, but of
importance in a more comprehensive understanding of the
delayed postprandial TG clearance in obese individuals.
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